CurifyLabs Oy

Based in Finland, CurifyLabs Oy specializes in the development of automated compounding systems designed for the personalized medicine sector, enhancing the efficiency and safety of medication manufacturing. CurifyLabs Oy, founded in 2021 and headquartered in Helsinki, Finland, focuses on the safe and efficient manufacturing of personalized medicines. The company has successfully completed 2 deals, with its most recent funding round, a Series A, occurring on May 27, 2025, where it raised EUR 6. 7 mn led by Springvest Oy.

The company has not undergone any noted pivots or changes in its strategy. CurifyLabs provides innovative solutions aimed at the safe and efficient manufacturing of personalized medicines. Their core offering revolves around a user-friendly platform that integrates four key technologies into an automated compounding system. This system utilizes GMP-manufactured Excipient Bases combined with Active Pharmaceutical Ingredients (APIs) to create customized medications in various dosage forms, including tablets, liquids, films, and suppositories.

The Pharma Printer, a desktop-sized automated compounding robot, facilitates the dispensing process, while the Formulation Library guides users through a validated compounding procedure, ensuring compliance with quality control standards. CurifyLabs primarily serves compounding pharmacies, healthcare providers, and patients who require tailored medication solutions, with a focus on international markets in Europe and North America. CurifyLabs generates revenue through a model that includes direct sales to healthcare providers and compounding pharmacies, as well as potential subscription services for access to their software solutions. Their flagship offering, centered around the Pharma Printer and its accompanying software, is designed to streamline the compounding process and improve medication safety.

Clients engage in transactions encompassing both the purchase of equipment and software licenses, creating multiple revenue streams for the company. In May 2025, CurifyLabs raised EUR 1 mn in venture debt funding from Business Finland Venture Capital, as part of a larger EUR 7. 7 mn Series A funding round. The company plans to utilize this funding to support product innovation and expansion plans.

Specific upcoming products are being designed to further enhance their compounding systems. CurifyLabs is also targeting expansion into new geographic markets, particularly focusing on regions with increasing demand for personalized medicine, which will be supported by the recent funding.